Smartphone app to help people with heart disease take medicines
Tests a smartphone app for medicine reminders in adults with heart disease.
Plain-language title generated from the registry record
Registry title: Effect of Smartphone Application (MED-AD) on Medication Adherence Among Patients With Cardiovascular Disease in Oman
Key facts
- Where
- Muscat, OmanSee the site
Where in Oman
- Ministry of HealthMuscat, OmanNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Sultan Qaboos University
- Trial code
- NCT06951451
- Record updated
- 30 April 2026
- Original description
This study aims to:Read full original descriptionShow less
Effect of Smartphone Application (MED-AD) on Medication Adherence Among Patients With Cardiovascular Disease in Oman: A Multicenter Randomized Clinical Trial
This study aims to:
1. Investigate the impact of MED-AD intervention on medication adherence among CVD patients, compared to patients receiving text message reminders or routine care alone at baseline, 6 months, and 12 months later. 2. Evaluate the effectiveness of MED-AD intervention on clinical outcomes among patients with CVD, compared to the outcomes of patients receiving text or routine care alone at baseline, 6 months, and 12 months later.
This study is a prospective randomized controlled clinical trial (RCT) with three arms:
1. MED-AD intervention: MED-AD is a smartphone application that will use the following strategies (pill reminders, Medication Adherence Report, medication intake confirmation, Medical Appointment Reminder, and educational notifications) to enhance medication adherence 2. Text message reminders: Participants will receive short text message (SMS) reminders to remind them to take medications as prescribed once daily 3. Routine care only: Participants will receive routine care that does not include text messages or reminders and education through an application.
Inclusion: diagnosed with at least one CVD (i.e., HTN, IHD, hyperlipidemia),; prescribed at least one medication for at least one year,; Omanis aged 18 years or older,; registered in the selected healthcare center, and 5) agreed to participate in the study.
Exclusion: have a severe cognitive impairment,; are unable to provide informed consent,; cannot read, and 4) do not have a smartphone with a compatible operating system (ios or Android).